Systems Approaches in Risk Assessment
暂无分享,去创建一个
[1] M. Danhof,et al. Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling—A New Classification of Biomarkers , 2005, Pharmaceutical Research.
[2] F. Leblond,et al. Drug metabolism in chronic renal failure. , 2003, Current drug metabolism.
[3] A. Halpern,et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. , 2005, The oncologist.
[4] Yong Hu,et al. Data mining methodologies for pharmacovigilance , 2012, SKDD.
[5] R. Iyengar,et al. Computation as the Mechanistic Bridge Between Precision Medicine and Systems Therapeutics , 2013, Clinical pharmacology and therapeutics.
[6] Darrell R Abernethy,et al. Systems pharmacology to predict drug toxicity: integration across levels of biological organization. , 2013, Annual review of pharmacology and toxicology.
[7] M. Hebert,et al. Measurement and Compartmental Modeling of the Effect of CYP3A5 Gene Variation on Systemic and Intrarenal Tacrolimus Disposition , 2012, Clinical pharmacology and therapeutics.
[8] A. Manz,et al. Revisiting lab-on-a-chip technology for drug discovery , 2012, Nature Reviews Drug Discovery.
[9] Balancing transparency and uncertainty. , 2012, Archives of internal medicine.
[10] P. Gillman,et al. A Review of Serotonin Toxicity Data: Implications for the Mechanisms of Antidepressant Drug Action , 2006, Biological Psychiatry.
[11] D. K. Arrell,et al. Network Systems Biology for Drug Discovery , 2010, Clinical pharmacology and therapeutics.
[12] D. Solís. US Food and Drug Administration , 2010 .
[13] S. Willmann,et al. Risk to the Breast‐Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study , 2009, Clinical pharmacology and therapeutics.
[14] H Derendorf,et al. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. , 1997, International journal of clinical pharmacology and therapeutics.
[15] Urs A Meyer,et al. Omics and drug response. , 2013, Annual review of pharmacology and toxicology.
[16] J. Hampe,et al. A Mechanistic, Model-Based Approach to Safety Assessment in Clinical Development , 2012, CPT: pharmacometrics & systems pharmacology.
[17] LJ Lesko,et al. Pharmacological Mechanism‐Based Drug Safety Assessment and Prediction , 2011, Clinical pharmacology and therapeutics.
[18] A. Henney,et al. The virtual liver: a multidisciplinary, multilevel challenge for systems biology , 2012, Wiley interdisciplinary reviews. Systems biology and medicine.
[19] Marc Schmidt,et al. Ras-independent Activation of the Raf/MEK/ERK Pathway upon Calcium-induced Differentiation of Keratinocytes* , 2000, The Journal of Biological Chemistry.
[20] Kenneth J Rothman,et al. The reporting odds ratio and its advantages over the proportional reporting ratio , 2004, Pharmacoepidemiology and drug safety.
[21] P. Imming,et al. Drugs, their targets and the nature and number of drug targets , 2006, Nature Reviews Drug Discovery.
[22] R. Altman,et al. Detecting Drug Interactions From Adverse‐Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose Levels , 2011, Clinical pharmacology and therapeutics.
[23] Isao Yoshimura,et al. Criteria Revision and Performance Comparison of Three Methods of Signal Detection Applied to the Spontaneous Reporting Database of a Pharmaceutical Manufacturer , 2007, Drug safety.
[24] I R Edwards,et al. Harmonisation in Pharmacovigilance , 1994, Drug safety.
[25] D. Ingber,et al. Reconstituting Organ-Level Lung Functions on a Chip , 2010, Science.
[26] Alfio Quarteroni,et al. A vision and strategy for the virtual physiological human in 2010 and beyond , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.
[27] Tudor I. Oprea,et al. Linking Pharmacology to Clinical Reports: Cyclobenzaprine and Its Possible Association With Serotonin Syndrome , 2011, Clinical pharmacology and therapeutics.
[28] M. Bush,et al. Probabilistic Risk Analysis: Improving Early Drug Development Decision Making , 2010, Clinical pharmacology and therapeutics.
[29] G. D. Dal Pan,et al. Regulatory Innovation in Postmarketing Risk Assessment and Management , 2012, Clinical pharmacology and therapeutics.
[30] R. Iyengar,et al. Merging Systems Biology with Pharmacodynamics , 2012, Science Translational Medicine.
[31] A. Bate,et al. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events , 2006, Statistics in medicine.
[32] J. Oliveira,et al. The EU‐ADR Web Platform: delivering advanced pharmacovigilance tools , 2013, Pharmacoepidemiology and drug safety.
[33] P B Watkins,et al. Drug Safety Sciences and the Bottleneck in Drug Development , 2011, Clinical pharmacology and therapeutics.
[34] Stephan Schmidt,et al. Application of a mechanism-based disease systems model for osteoporosis to clinical data , 2013, Journal of Pharmacokinetics and Pharmacodynamics.
[35] Max Petzold,et al. Percentage of Patients with Preventable Adverse Drug Reactions and Preventability of Adverse Drug Reactions – A Meta-Analysis , 2012, PloS one.
[36] D. Noble,et al. Systems Biology: An Approach , 2010, Clinical pharmacology and therapeutics.
[37] P. Corey,et al. Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .
[38] Seth I. Berger,et al. Role of systems pharmacology in understanding drug adverse events , 2011, Wiley interdisciplinary reviews. Systems biology and medicine.
[39] Laura Inés Furlong,et al. Automatic Filtering and Substantiation of Drug Safety Signals , 2012, PLoS Comput. Biol..
[40] Zhongxing Liao,et al. Reducing the toxicity of cancer therapy: recognizing needs, taking action , 2012, Nature Reviews Clinical Oncology.
[41] Denis Noble,et al. The Cardiac Physiome: perspectives for the future , 2009, Experimental physiology.
[42] Usama M. Fayyad,et al. Knowledge Discovery in Databases: An Overview , 1997, ILP.
[43] Stephan Schmidt,et al. Coping with time scales in disease systems analysis: application to bone remodeling , 2011, Journal of Pharmacokinetics and Pharmacodynamics.
[44] Steffen Borchers,et al. Integrating Cellular Metabolism into a Multiscale Whole-Body Model , 2012, PLoS Comput. Biol..
[45] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[46] A. Rostami-Hodjegan,et al. Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology , 2012, Clinical pharmacology and therapeutics.
[47] M. Ingelman-Sundberg,et al. Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.
[48] A. McCullough. RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors , 2013 .
[49] C. Friedman,et al. Detection of Pharmacovigilance‐Related Adverse Events Using Electronic Health Records and Automated Methods , 2012, Clinical pharmacology and therapeutics.
[50] P. H. van der Graaf,et al. Integrated Pharmacometrics and Systems Pharmacology Model-Based Analyses to Guide GnRH Receptor Modulator Development for Management of Endometriosis , 2012, CPT: pharmacometrics & systems pharmacology.
[51] William DuMouchel,et al. Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .
[52] S. Evans,et al. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports , 2001, Pharmacoepidemiology and drug safety.
[53] P Ryan,et al. Novel Data‐Mining Methodologies for Adverse Drug Event Discovery and Analysis , 2012, Clinical pharmacology and therapeutics.
[54] Nigam H. Shah,et al. The coming age of data-driven medicine: translational bioinformatics' next frontier , 2012, J. Am. Medical Informatics Assoc..
[55] Joseph M. Tonning,et al. Pharmacovigilance in the 21st Century: New Systematic Tools for an Old Problem , 2004, Pharmacotherapy.
[56] M. Nakajima,et al. microRNAs as mediators of drug toxicity. , 2013, Annual review of pharmacology and toxicology.
[57] Vincent Lemaire,et al. Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. , 2004, Journal of theoretical biology.
[58] Hua Xu,et al. Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs , 2012, J. Am. Medical Informatics Assoc..
[59] Stephen F Badylak,et al. RETRACTED: Engineered whole organs and complex tissues , 2012, The Lancet.